Contemporary OB/GYN/LinkedIn
Jan 18, 2026, 07:48
DSMB Review Confirms Safety of Brexanolone for PPD – Contemporary OB/GYN
Contemporary OB/GYN shared a post on LinkedIn:
“A phase 3 trial of Lipocine Inc.‘s oral formulation of brexanolone, LPCN 1154, for postpartum depression, will continue without any modification following the completion of a second independent Data Safety Monitoring Board review.
In the second and last review, the DSMB found no safety concerns in the trial.
More details and more on the makeup of the trial.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 28, 2026, 16:59Unlocking the Potential of Menstrual Blood in Health Testing – Global Women’s Health Innovation Conclave
-
Jan 28, 2026, 16:57New Insights on Oocyte Yield in Endometriosis and PCOM – RBMO
-
Jan 28, 2026, 16:51Transform Your Expertise with ESHRE eCampus Learning – ESHRE
-
Jan 28, 2026, 16:46Accelerate Your Growth at the AP3G National Meeting – ASRM
-
Jan 28, 2026, 16:43Debojit Saha: Unraveling Chromosomal Errors in Aging Human Eggs
-
Jan 28, 2026, 16:38Silvia Vannuccini: RBMO Highlights Key Insights on Adenomyosis Awareness
-
Jan 28, 2026, 16:32Maximilian Attwood: Challenging Medical Misogyny in Endometriosis Research
-
Jan 28, 2026, 16:29Ioakeim Sapantzoglou: New Perspectives on Fetal Growth Restriction and Genetic Testing
-
Jan 28, 2026, 16:26Enhancing Pre-Eclampsia Prediction with Doppler Indices – ISUOG